Blood is far more than a simple transport fluid-it's a dynamic tissue orchestrating oxygen delivery, immune defense, clotting precision, and cellular renewal every second of your life. In this lesson, you'll master how the bone marrow conducts hematopoiesis, how each cell line serves distinct survival functions, and how disruptions in this command center manifest as the anemias, coagulopathies, and malignancies you'll diagnose at the bedside. Understanding blood's intricate regulation transforms abstract lab values into clinical stories you can read and act upon.
A cardiac surgeon coordinates 15+ instrument exchanges per minute during complex procedures, each requiring precise timing and sterile technique. Your bone marrow coordinates the production of 200 billion red cells, 10 billion white cells, and 400 billion platelets daily through precisely regulated stem cell differentiation cascades.
📌 Remember: SLIM-PM for hematopoietic growth factors - Stem cell factor, Leukemia inhibitory factor, Interleukins (3,6,11), M-CSF, Platelet-derived growth factor, Megakaryocyte growth factor. Each factor targets specific progenitor populations with nanomolar binding affinities and triggers distinct transcriptional programs.
The hematopoietic hierarchy follows a precise organizational structure:
Hematopoietic Stem Cells (HSCs)
Committed Progenitors
| Cell Type | Normal Count | Lifespan | Production Rate | Key Growth Factors | Clinical Significance |
|---|---|---|---|---|---|
| Erythrocytes | 4.5-5.5 × 10¹²/L | 120 days | 200 billion/day | EPO, SCF, IL-3 | Anemia if <4.0 × 10¹²/L |
| Neutrophils | 2.0-7.5 × 10⁹/L | 6-8 hours | 100 billion/day | G-CSF, GM-CSF | Neutropenia if <1.5 × 10⁹/L |
| Platelets | 150-450 × 10⁹/L | 7-10 days | 400 billion/day | TPO, IL-11 | Thrombocytopenia if <150 × 10⁹/L |
| Lymphocytes | 1.0-4.0 × 10⁹/L | Days-years | 10 billion/day | IL-2, IL-7, IL-15 | Lymphopenia if <1.0 × 10⁹/L |
| Monocytes | 0.2-0.8 × 10⁹/L | 1-3 days | 5 billion/day | M-CSF, GM-CSF | Monocytosis if >0.8 × 10⁹/L |
💡 Master This: Hematopoietic stress responses follow predictable patterns - left shift (increased immature neutrophils >10%), reticulocytosis (>2% with anemia), and thrombocytosis (>450 × 10⁹/L) indicate appropriate bone marrow responses to infection, bleeding, or inflammation respectively.
Understanding the bone marrow microenvironment reveals how disruptions in stromal support, growth factor signaling, or stem cell niches lead to the diverse spectrum of hematologic disorders you'll encounter clinically.
An air traffic controller processes 300+ data points simultaneously while managing 50+ aircraft in 3-dimensional airspace, requiring split-second decisions with zero error tolerance. Your hematopoietic system processes thousands of molecular signals simultaneously through transcription factors, epigenetic modifiers, and signaling cascades that determine cell fate decisions with similar precision.
📌 Remember: GATA-PU-RUNX for key hematopoietic transcription factors - GATA-1 (erythroid/megakaryocytic), PU.1 (myeloid/lymphoid), RUNX1 (all lineages). Mutations in these master regulators cause >60% of acute leukemias through disrupted differentiation programs.
The molecular control of hematopoiesis operates through interconnected regulatory networks:
Transcriptional Control
Epigenetic Regulation
⭐ Clinical Pearl: JAK2 V617F mutation occurs in >95% of polycythemia vera, 50-60% of essential thrombocythemia, and 50-60% of primary myelofibrosis cases. The mutation creates constitutive kinase activity, leading to cytokine-independent growth and characteristic MPN phenotypes.
| Molecular Pathway | Key Proteins | Normal Function | Disease Association | Clinical Impact |
|---|---|---|---|---|
| JAK-STAT | JAK1/2/3, STAT3/5 | Cytokine signaling | MPNs, lymphomas | >90% of MPNs have JAK2/CALR/MPL mutations |
| PI3K-AKT | PI3K, AKT, mTOR | Cell survival | B-cell malignancies | 30-40% of DLBCL have pathway alterations |
| RAS-MAPK | RAS, RAF, MEK, ERK | Proliferation control | AML, ALL | 25-30% of AML have RAS pathway mutations |
| p53 Pathway | p53, MDM2, p21 | DNA damage response | Most hematologic cancers | >50% of high-grade lymphomas lose p53 |
| Apoptosis | BCL-2, BAX, BAK | Programmed cell death | CLL, follicular lymphoma | t(14;18) in 85% of follicular lymphomas |
These molecular mechanisms provide the foundation for understanding how genetic alterations drive the pathogenesis of blood disorders and guide targeted therapeutic approaches.
A Swiss watchmaker assembles 130+ precision components in a timepiece requiring micrometer accuracy, where each component must function in perfect synchronization for optimal performance. Your hemostatic system coordinates >30 coagulation proteins, platelet activation cascades, and fibrinolytic enzymes through precisely timed molecular interactions that maintain vascular integrity while preventing thrombosis.
📌 Remember: 1-2-5-10 for coagulation factor half-lives - Factor VII (4-6 hours), Factor IX (18-24 hours), Factor X (24-48 hours), Factor II (60-72 hours). This explains why warfarin effects develop over 3-5 days as longer-lived factors are depleted.
The hemostatic system operates through integrated phases:
Loading diagram…
Primary Hemostasis (1-3 minutes)
Secondary Hemostasis (3-10 minutes)
⭐ Clinical Pearl: PT/INR reflects extrinsic pathway (factors VII, X, V, II) and is sensitive to warfarin therapy. aPTT reflects intrinsic pathway (factors XII, XI, IX, VIII) and monitors heparin therapy. Normal PT with prolonged aPTT suggests factors VIII, IX, XI, XII deficiency.
| Coagulation Test | Normal Range | Pathway Tested | Clinical Applications | Interpretation |
|---|---|---|---|---|
| PT/INR | 11-13 sec/0.9-1.1 | Extrinsic + common | Warfarin monitoring | INR 2-3 for most indications |
| aPTT | 25-35 seconds | Intrinsic + common | Heparin monitoring | 1.5-2.5x normal for therapy |
| Thrombin Time | 14-18 seconds | Fibrinogen → fibrin | Fibrinogen disorders | >20 sec suggests dysfunction |
| Fibrinogen | 200-400 mg/dL | Clot formation | DIC, liver disease | <100 mg/dL bleeding risk |
| D-dimer | <500 ng/mL | Fibrinolysis | Thrombosis screening | >500 ng/mL suggests clot breakdown |
Understanding hemostatic balance reveals how inherited bleeding disorders, acquired coagulopathies, and thrombotic conditions disrupt this precisely regulated system.
A radiologist analyzes >1,000 image slices in a single CT scan, identifying subtle density differences of <10 Hounsfield units that distinguish normal from pathologic tissue. Your hematologic diagnostic approach requires similar pattern recognition skills, analyzing cellular morphology, flow cytometry data, and molecular markers to distinguish between dozens of blood disorders with overlapping presentations.
📌 Remember: CLAMS for flow cytometry B-cell markers - CD19 (pan-B), CD20 (mature B), CD10 (germinal center), CD5 (CLL/mantle cell), Surface Ig (clonality). Aberrant expression patterns distinguish reactive from neoplastic B-cell populations with >95% accuracy.
The diagnostic approach follows systematic evaluation:
Morphologic Assessment
Flow Cytometry Analysis
⭐ Clinical Pearl: Bone marrow biopsy is indicated when peripheral blood findings are unexplained, suspected hematologic malignancy, or staging lymphoma. Dry tap (inability to aspirate) suggests myelofibrosis, hairy cell leukemia, or metastatic disease in >80% of cases.
| Diagnostic Test | Sample Required | Turnaround Time | Clinical Applications | Diagnostic Yield |
|---|---|---|---|---|
| CBC with differential | 3-5 mL EDTA | 2-4 hours | Screening, monitoring | >90% sensitivity for cytopenias |
| Flow cytometry | 5-10 mL EDTA/heparin | 24-48 hours | Leukemia/lymphoma diagnosis | >95% accuracy for lineage |
| Bone marrow biopsy | Core biopsy + aspirate | 3-5 days | Definitive diagnosis | >98% for hematologic malignancies |
| Cytogenetics | Bone marrow/blood | 7-14 days | Prognosis, targeted therapy | 80-90% metaphase success rate |
| Molecular studies | Various samples | 3-7 days | Minimal residual disease | 10⁻⁴ to 10⁻⁶ sensitivity |
These diagnostic tools provide the foundation for accurate classification, risk stratification, and treatment selection in hematologic disorders, connecting laboratory findings to clinical outcomes.
A cardiac surgeon performs >500 precise sutures during complex procedures, each requiring specific tension and optimal placement for successful outcomes. Your hematologic treatment decisions require similar precision, selecting from >100 available agents with distinct mechanisms, dosing requirements, and toxicity profiles to achieve optimal therapeutic outcomes while minimizing adverse effects.
📌 Remember: CHOP-R for lymphoma chemotherapy - Cyclophosphamide (750 mg/m²), Hydroxydaunorubicin/doxorubicin (50 mg/m²), Oncovin/vincristine (1.4 mg/m²), Prednisolone (100 mg/m²), Rituximab (375 mg/m²). This regimen achieves complete remission in >80% of diffuse large B-cell lymphoma patients.
Modern hematologic therapeutics operates through multiple modalities:
Loading diagram…
Targeted Therapy Revolution
Cellular Immunotherapy
⭐ Clinical Pearl: Tumor lysis syndrome risk increases with high tumor burden (WBC >50,000/μL, LDH >2x normal), rapid proliferation, and chemosensitive malignancies. Prophylaxis with allopurinol (300-600 mg daily) or rasburicase (0.2 mg/kg) prevents uric acid nephropathy in >95% of high-risk patients.
| Treatment Category | Mechanism | Response Rates | Key Toxicities | Monitoring Requirements |
|---|---|---|---|---|
| Alkylating agents | DNA cross-linking | 60-80% in lymphomas | Myelosuppression, infertility | CBC weekly during treatment |
| Antimetabolites | DNA synthesis inhibition | 70-90% in ALL | Mucositis, hepatotoxicity | Methotrexate levels if high-dose |
| Anthracyclines | DNA intercalation | 50-70% in AML | Cardiomyopathy | ECHO/MUGA every 3-4 cycles |
| Targeted therapy | Specific pathway inhibition | 80-95% in appropriate targets | Specific to target | Molecular monitoring for resistance |
| Immunotherapy | Immune system activation | Variable by disease | Autoimmune reactions | Cytokine levels, organ function |
These therapeutic advances have transformed outcomes in hematologic malignancies, with 5-year survival rates improving from <30% to >70% in many diseases over the past two decades.
A NASA mission control team monitors >10,000 telemetry parameters simultaneously across multiple spacecraft systems, making real-time adjustments based on predictive algorithms and risk assessment models. Your advanced hematologic practice requires similar systems thinking, integrating genomic data, biomarkers, clinical parameters, and treatment response patterns to optimize personalized therapy decisions.
📌 Remember: MDS-RISK for myelodysplastic syndrome prognosis - Marrow blasts (<5%, 5-10%, 11-20%, >20%), Dysplastic lineages (1, 2, 3), Sex chromosome abnormalities, Ring sideroblasts, International Prognostic Scoring System, Survival correlation. IPSS-R scores predict median survival from 0.8 years (very high risk) to 8.8 years (very low risk).
The integration of precision medicine approaches revolutionizes hematologic care:
Genomic Risk Stratification
Biomarker-Driven Therapy
⭐ Clinical Pearl: Circulating tumor DNA (ctDNA) monitoring provides real-time assessment of treatment response and early relapse detection in lymphomas. ctDNA clearance by cycle 2 predicts progression-free survival >90% at 2 years, while persistent ctDNA indicates treatment resistance requiring therapy modification.
| Precision Medicine Tool | Technology | Clinical Application | Sensitivity | Impact on Outcomes |
|---|---|---|---|---|
| Next-gen sequencing | Targeted panels | Mutation profiling | 1-5% variant frequency | Guides targeted therapy in >60% |
| Flow cytometry MRD | Multiparameter | Leukemia monitoring | 0.01% (10⁻⁴) | Predicts relapse with >85% accuracy |
| Liquid biopsy | ctDNA analysis | Non-invasive monitoring | 0.1-1% tumor fraction | Early relapse detection 2-6 months before imaging |
| Pharmacogenomics | Germline testing | Drug dosing optimization | >99% genotype accuracy | Reduces toxicity by 30-50% |
| Proteomics | Mass spectrometry | Biomarker discovery | ng/mL protein levels | Novel targets in >40% of studies |
| %%{init: {'flowchart': {'htmlLabels': true}}}%% | ||||
| flowchart TD |
Start["👤 Patient Presentation
• Clinical evaluation• Medical history"]
Genomic["🔬 Genomic Profiling
• Comprehensive panel• Variant analysis"]
MutationDec["📋 Actionable?
• Evaluate mutations• Target assessment"]
Targeted["💊 Targeted Therapy
• Selection of agent• Precision medicine"]
Standard["💊 Standard Treatment
• Guideline therapy• Conventional chemo"]
MRDMon["👁️ MRD Monitoring
• Track disease burden• Serial testing"]
MRDDec["📋 MRD Status
• Test results• Residual disease"]
Continue["✅ Continue Therapy
• Maintain regimen• Observation phase"]
Intensify["⚠️ Intensification
• Escalate treatment• Change strategy"]
ctDNA["🔬 ctDNA Reassess
• Liquid biopsy• Genetic tracking"]
RespDec["📋 Response?
• Clinical response• Scan biomarkers"]
Maint["💊 Maintenance
• Long-term strategy• Relapse prevention"]
Trial["⚠️ Clinical Trial
• Novel agents• Research study"]
Start --> Genomic Genomic --> MutationDec MutationDec -->|Yes| Targeted MutationDec -->|No| Standard Targeted --> MRDMon Standard --> MRDMon MRDMon --> MRDDec MRDDec -->|Negative| Continue MRDDec -->|Positive| Intensify Intensify --> ctDNA ctDNA --> RespDec RespDec -->|Yes| Maint RespDec -->|No| Trial
style Start fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8 style Genomic fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style MutationDec fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Targeted fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style Standard fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style MRDMon fill:#EEFAFF, stroke:#DAF3FF, stroke-width:1.5px, rx:12, ry:12, color:#0369A1 style MRDDec fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Continue fill:#F6F5F5, stroke:#E7E6E6, stroke-width:1.5px, rx:12, ry:12, color:#525252 style Intensify fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C style ctDNA fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style RespDec fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Maint fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534 style Trial fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C
> 💡 **Master This**: **Clonal evolution** drives treatment resistance in hematologic malignancies. **Serial genomic monitoring** reveals **emergence of resistance mutations** in **>70%** of relapsed cases, enabling **preemptive therapy changes** and **combination strategies** to prevent **clonal selection** and **improve long-term outcomes**.
This integrated approach transforms hematologic care from **empirical treatment** to **precision medicine**, improving **response rates** from **60-70%** to **>85%** in many diseases while reducing **treatment-related toxicity** by **30-40%** through **personalized dosing** and **biomarker-guided therapy selection**.
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
1. Which of the following is NOT a characteristic feature of paroxysmal nocturnal hemoglobinuria?
Answer: A. High LAP
> Key point: PNH is associated with low—not high—leukocyte alkaline phosphatase (LAP) activity. Why High LAP is correct - LAP is a GPI-anchored protein, and affected PNH granulocytes have reduced LAP activity; therefore, high LAP is not characteristic. How they compare | Feature | Relation to PNH | |---|---| | High LAP | Not characteristic; LAP activity is reduced | | Intravascular hemolysis | Characteristic | | Thrombocytopenia | May accompany marrow failure and cytopenias | | Thrombosis | Characteristic complication | Why the other options are wrong - Intravascular hemolysis: Complement-mediated red-cell destruction is a hallmark of PNH. - Thrombocytopenia: It may occur with the marrow failure and cytopenias associated with PNH. - Thrombosis: PNH carries an increased risk of thrombosis, including at unusual venous sites.
2. A 59-year-old male presents with multiple neck swellings, fever, and weight loss for 6 months. General examination reveals painless lymphadenopathy in the neck, and blood investigations show anemia. Lymph node biopsy reveals cells with a delicate multilobed, 'popped corn' nucleus. Which variant of lymphoma is this?
Answer: B. Lymphocyte predominant
> Key point: “Popcorn” cells with multilobed nuclei identify lymphocyte-predominant Hodgkin lymphoma. Why Lymphocyte predominant is correct - The delicate, multilobed “popcorn” nucleus is characteristic of lymphocytic and histiocytic cells in this variant. - The biopsy morphology therefore points to lymphocyte-predominant Hodgkin lymphoma. Why the other options are wrong - Lymphocyte-rich classical: Features classic Reed–Sternberg cells in a lymphocyte-rich background, not popcorn cells. - Lymphocyte depletion: Features numerous pleomorphic Reed–Sternberg cells and few background lymphocytes. - Nodular sclerosis: Characterized by collagen bands and lacunar cells, not the described popcorn cells.
3. The image shows:
Answer: C. Thalassemia major
> Key point: Thalassemia major causes chronic marrow expansion and characteristic facial changes, with target cells and nucleated red blood cells. Why Thalassemia major is correct - Chronic ineffective erythropoiesis expands the marrow, producing facial changes such as frontal bossing and malar prominence. - Target cells and nucleated red blood cells support severe thalassemia. Why the other options are wrong - Hereditary spherocytosis: typically shows spherocytes rather than the described target cells and nucleated red blood cells. - Autoimmune hemolytic anemia: more typically shows spherocytes and polychromasia; the described chronic marrow-expansion features favor thalassemia. - G6PD deficiency: causes episodic hemolysis, with Heinz bodies or bite cells during crises, rather than the described chronic features.
4. What is the typical bone marrow finding in myelofibrosis?
Answer: D. Dry tap
> Key point: Myelofibrosis characteristically produces a dry tap because fibrosis impedes marrow aspiration. Why Dry tap is correct - Fibrotic marrow is difficult to aspirate, so the typical finding is a dry tap. How they compare | Finding | What it suggests | |---|---| | Dry tap | Myelofibrosis; fibrosis impedes aspiration | | Ring-sideroblast-rich aspirate | Sideroblastic erythropoiesis | | Megaloblast-rich aspirate | Megaloblastic hematopoiesis | | Plasma-cell-rich aspirate | Plasma-cell proliferation or reactive plasmacytosis | Why the other options are wrong - Ring-sideroblast-rich aspirate: suggests sideroblastic erythropoiesis, not the characteristic aspiration result of myelofibrosis. - Megaloblast-rich aspirate: suggests megaloblastic hematopoiesis, often from vitamin B12 or folate deficiency. - Plasma-cell-rich aspirate: suggests plasma-cell proliferation or reactive plasmacytosis.
5. Which of the following are neonatal complications of maternal diabetes during pregnancy? I. Hyperbilirubinemia II. Hypocalcemia III. Cardiomyopathy IV. Hypoglycemia Select the correct answer using the code given below :
Answer: B. I, II and IV
I, II and IV - The mapped answer identifies hyperbilirubinemia, hypocalcemia, and hypoglycemia as the common metabolic complications requiring routine monitoring in infants of diabetic mothers. - Cardiomyopathy is also recognized, so the stem is limited because no option includes all four; this answer reflects the supplied emphasis on the common metabolic triad. I, II and III - This includes hyperbilirubinemia, hypocalcemia, and cardiomyopathy, all recognized neonatal complications of maternal diabetes. - The mapped answer excludes this combination because it omits hypoglycemia, the most frequent complication caused by persistent neonatal hyperinsulinemia after maternal glucose delivery stops. II, III and IV - This includes hypocalcemia, cardiomyopathy, and hypoglycemia, which are recognized complications in infants of diabetic mothers. - The mapped answer excludes this combination because it omits hyperbilirubinemia, associated with polycythemia, increased red-cell breakdown, and impaired hepatic conjugation. I, III and IV - This includes hyperbilirubinemia, cardiomyopathy, and hypoglycemia, all recognized neonatal complications of maternal diabetes. - The mapped answer excludes this combination because it omits hypocalcemia, which may result from impaired parathyroid hormone response, hypomagnesemia, and altered calcium–phosphorus metabolism.
6. A newborn presents with the clinical features shown in the image below. What is the most likely diagnosis?
Answer: C. Trisomy 18
18 trisomy - The image shows a newborn with characteristic clenched hands with overlapping fingers, which are common features of Trisomy 18 (Edwards syndrome). - Other typical features include low-set ears, micrognathia, rocker-bottom feet, omphalocele, and severe developmental delay, contributing to a poor prognosis. 21 trisomy - Trisomy 21 (Down syndrome) typically presents with upslanting palpebral fissures, an epicanthal fold, a single palmar crease, and intellectual disability, which are not the prominent features seen here. - While congenital heart defects can be present in both, the specific hand posture and omphalocele are more indicative of Trisomy 18. 13 trisomy - Trisomy 13 (Patau syndrome) is characterized by severe malformations, including cleft lip and palate, polydactyly, cutis aplasia, and microphthalmia, which are distinct from the features in the image. - Holoprosencephaly is also common in Trisomy 13, which is not suggested by the visual findings. 12 trisomy - Trisomy 12 is not a recognized viable chromosomal aneuploidy in humans that leads to a distinct syndrome such as those related to chromosomes 13, 18, or 21. - Genetic disorders involving chromosome 12 are typically mosaic or involve partial aneuploidies.
7. A 10-month-old boy presents with coarse facies and developmental delay. Examination reveals hepatosplenomegaly, and leukocyte N-acetylglucosamine-1-phosphotransferase activity is absent. What is the diagnosis?
Answer: D. I cell disease
> Key point: Absent N-acetylglucosamine-1-phosphotransferase activity identifies I-cell disease. Why I cell disease is correct - This enzyme is needed to tag lysosomal enzymes for proper targeting; its absence is the defining clue for I-cell disease. - The coarse facies, developmental delay, and hepatosplenomegaly fit the described storage disorder. Why the other options are wrong - MPS type I: Results from alpha-L-iduronidase deficiency, not absent phosphotransferase activity. - GM1 gangliosidosis: Results from beta-galactosidase deficiency. - MPS type II: Results from iduronate sulfatase deficiency, not absent phosphotransferase activity.
8. A 5 year old child presented with periorbital swelling and oliguria. Nephrotic syndrome is suspected. Which of the following is the commonest type of nephrotic syndrome in this child?
Answer: C. Minimal change disease
Minimal change disease - Minimal change disease is the commonest cause of nephrotic syndrome in children, accounting for approximately 80% of cases. - Sudden periorbital edema, generalized edema, and oliguria due to severe proteinuria are consistent with this childhood presentation. Chronic glomerulonephritis - Chronic glomerulonephritis usually has an insidious course with hematuria and hypertension, features not described in this child’s acute nephrotic presentation. - Its typical nephritic features distinguish it from the sudden periorbital edema, generalized edema, and oliguria associated with childhood nephrotic syndrome. Focal segmental glomerulosclerosis (FSGS) - FSGS is an important cause of childhood nephrotic syndrome but is less common than minimal change disease in this age group. - FSGS is associated with a poorer steroid response and greater risk of progression to end-stage renal disease, rather than being the commonest type. Congenital nephrotic syndrome - Congenital nephrotic syndrome is a rare genetic condition that typically presents within the first 3 months of life, not at 5 years of age. - Its characteristic severe proteinuria from birth and association with inherited syndromes make it inconsistent with this child’s later presentation.
9. A newborn has profuse umbilical stump bleeding. Platelet count and morphology are normal; PT and APTT are normal, aggregation is absent with ADP and collagen, and the ristocetin response is preserved. What is the most likely diagnosis?
Answer: C. Glanzmann thrombasthenia
> Key point: Absent ADP- and collagen-induced aggregation with a preserved ristocetin response points to Glanzmann thrombasthenia. Why Glanzmann thrombasthenia is correct - Platelet count and morphology are normal, but aggregation with ADP and collagen is absent. - Preserved ristocetin response distinguishes this pattern from disorders affecting ristocetin-dependent platelet function; normal PT and APTT fit a platelet-function disorder. Clues in the question | Clue | What it points to | |---|---| | Normal platelet count and morphology | Not the typical Bernard-Soulier pattern | | Absent aggregation with ADP and collagen | Glanzmann thrombasthenia | | Preserved ristocetin response | Argues against Bernard-Soulier syndrome and von Willebrand disease | | Normal PT and APTT | Argues against factor X deficiency | Why the other options are wrong - Bernard-Soulier syndrome: typically has giant platelets, thrombocytopenia, and an abnormal ristocetin response. - Factor X deficiency: significant deficiency generally prolongs both PT and APTT. - Von Willebrand disease: impairs the ristocetin-dependent response, which is preserved here. > Common trap: Umbilical stump bleeding with normal screening tests can suggest factor XIII deficiency, but the platelet aggregation pattern here identifies Glanzmann thrombasthenia.
10. A 1-year-old child who has received only breast milk has hemoglobin 9.2 g/dL and MCV 108 fL. The peripheral blood smear is shown. Which investigation is most appropriate next?
Answer: C. Serum cobalamin and folate
> Key point: Macrocytosis with hypersegmented neutrophils suggests megaloblastic anemia; check cobalamin and folate first. Why serum cobalamin and folate is correct - The elevated MCV and blood-film pattern point to megaloblastic anemia. - Serum cobalamin and folate assess the likely nutritional causes. Why the other options are wrong - Bone marrow aspiration: It is not the initial investigation when the peripheral findings suggest a nutritional cause. - Serum ferritin and iron: These assess iron status; isolated iron deficiency usually causes microcytosis, not the pattern shown. - Hemoglobin electrophoresis: It investigates hemoglobinopathies, not this megaloblastic blood-film pattern.
1. Both acute lymphoblastic and acute myeloid leukemia in children are associated with anemia.
fanconi
2. Kostmann syndrome can evolve into leukemia
acute myeloid
3. _____ leukemia is associated with _____ syndrome; usually arises _____ the age of 5
Acute megakaryoblastic · Down · before
4. Beta-thalassemia _____ is characterized by expansion of hematopoiesis into facial bones, leading to "_____ facies"
major · chipmunk
5. On complete blood count, patients with Systemic Juvenile Idiopathic Arthritis will frequently present with: - _____ RBCs - _____ WBCs - _____ Platelets
decreased · increased · increased
6. _____ syndrome is a syndrome of _____ and _____ in a patient of _____
Kasabach-Merritt · thrombocytopenia · consumptive coagulopathy · hemangioma
7. _____ is a common presenting sign of sickle cell anemia in _____ (age group)
Dactylitis · infants
8. Kids with sickle cell disease should undergo _____ starting at age of _____ yrs to reduce the incidence of overt stroke
transcranial doppler ultrasound · 2
9. _____ leukemia is associated with _____ syndrome; usually arises _____ the age of 5 years
Acute lymphoblastic · Down · after
10. Kids with sickle cell disease should undergo _____ starting at age of _____ yrs to reduce the incidence of retinopathy
annual ophthalmology screen · 10
Get full Oncourse access with lessons, practice questions, flashcards and AI study tools.
Scan to download app
Enter your email to get your 75% OFF code and unlock the full Indian Medical PG question bank on the app.